

# **Studi sulla neoplasia pancreaticata**

Gruppo AIRO GI

Dott.ssa A. Arcelli

# IRENE 1

Phase II multicenter trial: anticipated SBRT combined with CHT in LAPC

I<sup>^</sup> endpoint: resectability rate


II<sup>^</sup> endpoints: LC, DMFS, OS, toxicity

✓ SBRT (30 Gy/5 fx) between I<sup>^</sup>-II<sup>^</sup> cycles CHT

✓ CHT: FOLFIRINOX

✓ CHT continued until week 20<sup>^</sup> post-SBRT

✓ Re-evaluation: ce CT, based on RECIST criteria, for potential surgical intervention



# IRENE 1

## RESULTS:

- ✓ 14 enrolled LAPC (12 BO-2 Aviano) (2018-2022)
- ✓ median FU: 24 months (range: 8-39)
- ✓ CHT regimens: gemcitabine + Nab Paclitaxel (14.2%) and FOLFIRINOX (85.8%)
- ✓ median tumor diameter: 4.0 cm (range: 2.0-7.0 cm)
- ✓ Resectability rate: 21.4% (two R0 and one R1 resections)
- ✓ Grade 3 GI late toxicity: 1 (gastric ulcer)
- ✓ Median, 2-year OS, LC, DMFS rates were 24, 20, and 10 months; 38.5%, 36.4%, and 31.3%
- ✓ Median OS was significantly higher in pancreatic body tumors compared to head tumors (38 vs 22 months,  $p=0.05$ )

***Anticipated SBRT in combination with modern CHT regimens appears effective and well-tolerated***

**[alessandra.arcelli@aosp.bo.it](mailto:alessandra.arcelli@aosp.bo.it)**